# Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

> **NCT07301424** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Alberta** · enrollment: 80 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
- BCR-ABL Positive Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Treatment with blinatumomab given subcutaneously.

## Key facts

- **NCT ID:** NCT07301424
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2031-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07301424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07301424, "Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07301424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*